

6. Literaturverzeichnis

1. Böhm M, Diet F, Feiler G, Kemkes B, Erdmann E: α -adrenoceptors and α -adrenoceptor mediated positiv inotropic effects in failing human myocardium. *J Cardiovasc Pharmacol* **12** (1988); 357-361
2. Bowditch HP: Über die Eigenthümlichkeiten der Reizbarkeit, welche die Muskelfasern des Herzens zeigen. Berichte über die Verhandlungen der Königlich Sächsischen Gesellschaft zu Leipzig. *Mathematisch-Physische Classe* **23** (1871): 652–689
3. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* **72** (1976): 248-254
4. Bristow MR: Changes in myocardial and vascular receptors in heart failure. *J Am Coll Cardiol* **22 (Suppl A)** (1993); 61A-71A
5. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB: Decreased catecholamine sensitivity and β -adrenergic-receptor density in failing human hearts. *N Engl J Med* **307** (1982); 205-211
6. Bristow MR, Minobe W, Rasmussen R, Larrabee P, Skerl L, Klein JW, Anderson FL, Murray J, Mestroni L, Karwande SV: β -adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. *J Clin Invest* **89** (1992); 803-815
7. Bristow MR, Minobe W, Rasmussen R, Hersberger RE, Hoffman BB: Alpha1-adrenergic receptors in the nonfailing and failing heart. *J Pharmacol Exp Ther* **247** (1988); 1039-1045

8. Brodde O-E: β_1 - and β_2 -Adrenoceptors in the human heart: properties, function and alterations in chronic heart failure. *Pharmacol Rev* **43** (1991); 203-242
9. Brodde O-E, Michel MC: Adrenergic and muscarinergic receptors in the human heart. *Pharmacol Rev* **51** (1999); 651-689
10. Brodde O-E, Michel MC, Zerkowski H-R: Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure. *Cardiovasc Res* **30** (1995); 570-587
11. Brodde O-E, Pönicke K, Goldberg M: In adult rat cardiomyocytes noradrenaline-induced hypertrophic response is inhibited by β_1 adrenoceptor stimulation and by pertussis toxin treatment. *FASEB J* **15** (2001); A 230 (Abstr.)
12. Brown L, Miller J, Dagger A, Sernia C: Cardiac and vascular responses after monocrotaline-induced hypertrophy in rats. *J Cardiovasc Pharmacol* **31** (1998); 108-115
13. Bruner LH, Carpenter LJ, Hamlow P, Roth RA: Effect of a mixed function oxidase inducer and inhibitor on monocrotaline pyrrole pneumotoxicity. *Toxicol Appl Pharmacol* **85** (1986); 416-427
14. Bugaisky LB, Gupta M, Gupta MP, Zak R: Cellular and molekular mechanisms of cardiac hypertrophy. In: *The heart and Cardiovascular System (2nd. ed.)*, edited by H.A. Fozzard. New York: Raven, 1992, p. 1621-1640
15. Clark WA, Rudnik SJ, Simpson DG, LaPres JJ, Decker RS: Cultured adult cardiac myocytes maintain protein synthetic capacity of intact adult hearts. *Am J Physiol* **265** (1993); H573-H582

16. Decker RS, Cook MG, Behnke-Barclay MM, Decker ML, Lesch M, Samarel AM: Catecholamines modulate protein turnover in cultured, quiescent rabbit cardiomyocytes. *Am J Physiol* **265** (1993); H329-H339
17. Dennis P, Vaughan-Williams EM: Hypoxic cardiac hypertrophy is not inhibited by cardioselective or non-selective β -adrenoceptor antagonists. *J Physiol* **324** (1982); 365-374
18. Doggrell SA, Brown L: Rat models of hypertension, cardiac hypertrophy and failure. *Cardiovasc Res.* **39**(1998); 89-105
19. Dooley DJ, Bittiger H, Reymann NC: CGP 20712 A: A useful tool for quantitating β_1 - and β_2 -adrenoceptors. *Eur J Pharmacol* **130** (1986); 137-139
20. Feldman MD, Copelas L, Gwathmey JK: Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. *Circulation* **75** (1987); 331-339
21. Ferrara N, Davia K, Abete P, Rengo F, Harding SE: Alterations in β -adrenoceptor mechanisms in the aging heart: Relationship with heart failure. *Aging Clin Exp Res* **9** (1997);391-403
22. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR: Assessment of the β -adrenergic receptor pathway in the intact and failing human heart: progressive receptor downregulation and subsensitivity to agonist response. *Circulation* **74** (1986); 1290-1309
23. Ghodsi F, Will JA: Changes in pulmonary structure and function induced by monocrotaline intoxication. *Am J Physiol.* **240** (1981); H149-H155
24. Goldstein GS: Plasma catecholamines and essential hypertension: an analytical review. *Hypertension* **5** (1988); 86-99

25. Guyton AC, Taylor AE, Granger HJ: Dynamics and control of body fluids. *Circulatory physiology II*, Saunders, Philadelphia (1975).
26. Hasenfuss G: Animal models of human cardiovascular disease, heart failure and hypertrophy. *Cardiovasc Res.* **39** (1998); 60-76
27. Hoorn CM, Wagner JG, Roth RA: Effects of monocrotaline pyrrole on cultured rat pulmonary endothelium. *Toxicol Appl Pharmacol* **120** (1993); 281-287
28. Hwang K-C, Gray CD, Sweet WE, Moravec CS, Im M-J: α_1 -adrenergic receptor coupling with G_h in the failing human heart. *Circulation* **94** (1996); 718-726
29. Ishikawa S, Honda M, Yamada S, Morioka S, Moriyama K: Biventricular downregulation of β -adrenergic receptors in right ventricular hypertrophy induced by monocrotaline. *Jpn Circ J* **55** (1991); 1077-1085
30. Iwakura K, Hori M, Watanabe Y, Kitabatake A, Cragoe EJ Jr, Yoshida H, Kamada T: α_1 -Adrenoceptor stimulation increases intracellular pH and Ca^{2+} in cardiomyocytes through Na^+/H^+ and Na^+/Ca^{2+} exchange. *Eur J Pharmacol* **186** (1990); 29-40
31. Kashara Y, Kiyatake K, Tatsumi K, Subito K, Kakusaka I, Yamagata S, Ohmori S, Kitada M, Kuriyama T: Bioactivation of monocrotaline by P-450 3A in rat liver. *J Cardiovasc Pharmacol* **30** (1997); 124-129
32. Kaumann AJ, Molenaar P: Modulation of human cardiac function through 4 β -adrenoceptor populations. *Naunyn-Schmiedeberg's Arch Pharmacol* **355** (1997); 667-681
33. Lalich JJ, Merkow L: Pulmonary arteritis produced in rats feeding *crotalaria spectabilis*. *Lab Invest* **10** (1961); 744-750

34. Leineweber K, Seyfarth T, Abraham G, Gerbershagen H-P, Heinroth-Hoffmann I, Pönicke K, Brodde O-E: Cardiac β -adrenoceptor changes in monocrotaline-treated rats: differences between membrane preparations from whole ventricles and isolated ventricular cardiomyocytes. *J Cardiovasc Pharmacol* **41** (2003); 333-342
35. Limas CJ, Limas C, Goldenberg IF: Intracellular distribution of adrenoceptors in the failing human myocardium. *Am Heart J* **117** (1989); 1310-1316
36. Lohse MJ: G-protein-coupled receptor kinases and the heart. *Trends Cardiovasc Med* **5** (1995); 63-65
37. Meyrick B, Brigham KL: Repeated Escherichia coli endotoxin-induced pulmonary inflammation causes chronic pulmonary hypertension in sheep. Structural and functional changes. *Lab Invest* **55** (1986); 164-176
38. Meyrick B, Gamble W, Reid L: Development of Crotalaria pulmonary hypertension: hemodynamic and structural study. *Am J Physiol* **239** (1981); H692-H702.
39. Michel MC, Kenny B, Schwinn DA: Classification of α_1 -adrenoceptor subtypes. *Naunyn-Schmiedeberg's Arch Pharmacol* **352** (1995): 1-10
40. Michel MC, Hanft G, Groß G: Radioligand binding studies of α_1 -adrenoceptor subtypes in rat heart. *Br J Pharmacol* **111** (1994); 533-538
41. Michel RP, Smith TT, Poulsen RS: Distribution of fluid in bronchovascular bundles with permeability lung edema induced by α -naphthyl-thiourea in dogs – a morphometric study. *Lab Invest* **51** (1984); 97-103
42. Morgan HE, Baker KM: Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. *Circulation* **83** (1991); 13-25

43. Noel J, Pouyssegur J: Hormonal regulation, pharmacology and membrane sorting of vertebrate Na⁺-H⁺-exchanger isoforms. *Am J Physiol* **268** (1995); C2283-C2296
44. Pan LC, Lamé MW, Morin D, Wilson DW, Segall HJ: Red blood cells augment transport of reactive metabolites of monocrotaline from liver to lung in isolated and tandem liver and lung preparations. *Toxicol Appl Pharmacol* **110** (1991); 336-446
45. Parker TG, Packer SE, Schneider MD: Growth factors, protooncogenes and plasticity of the cardiac phenotype. *Annu Rev Physiol* **53** (1991); 179-200
46. Pönicke K, Heinroth-Hoffmann I, Brodde O-E: Differential effects of bucindolol and carvedilol on noradrenalin-induced hypertrophic response in ventricular cardiomyocytes of adult rats. *J Pharmacol Exp Ther* **301** (2002); 71-76
47. Pönicke K, Schlüter KD, Heinroth-Hoffmann I, Seyfarth T, Goldberg M, Osten B, Piper H-M, Brodde O-E: Noradrenalin-induced increase in protein synthesis is mediated by α_{1A} -adrenoceptors in adult rat ventricular cardiomyocytes. *Naunyn-Schmiedeberg's Arch Pharmacol* **364** (2001); 444-453
48. Pönicke K, Vogelsang M, Heinroth M, Becker K, Zolk O, Böhm M, Zerkowski HR, Brodde O-E: Endothelin receptors in the nonfailing and the failing human heart. *Circulation* **97** (1998); 744-751
49. Reindel JF, Ganey PE, Wagner JG, Slocombe RF, Roth RA: Development of morphologic, hemodynamic, and biological changes in lungs of rats given monocrotaline pyrrole. *Toxicol Appl Pharmacol* **106** (1990); 179-200
50. Roskamm H, Reindell H: *Herzkrankheiten; 2. Aufl.* ,Springer, Berlin (1982).

51. Schäfer M, Pönicke K, Heinroth-Hoffmann I, Brodde O-E, Piper HM, Schlüter KD: β -adrenoceptor stimulation attenuates the hypertrophic effect of α -adrenoceptor stimulation in adult rat ventricular cardiomyocytes. *J Am Coll Cardiol* **37** (2001); 300-307
52. Schäfers RF, Poller U, Pönicke K, Geissler M, Daul AE, Michel MC, Brodde O-E: Influence of adrenoceptor and muscarinic receptor blockade on the cardiovascular effects of exogenous noradrenaline and endogenous noradrenaline released by infused tyramine. *Naunyn-Schmiedeberg's Arch Pharmacol* **355** (1997); 239-249
53. Schlüter KD, Piper H: Regulation of growth in the adult cardiomyocytes. *FASEB J* **13 (Suppl)** (1999); 317-322
54. Schultze AE, Roth RA: Chronic pulmonary hypertension – the monocrotaline model and involvement of the hemostatic system. *J Toxicol Environ Health B Crit Rev* **1** (1998); 271-346
55. Seyfarth T, Gerbershagen H-P, Giessler C, Leineweber K, Heinroth-Hoffmann I, Pönicke K, Brodde O-E: The cardiac β -adrenoceptor-G-protein(s)-adenyl-cyclase system in monocrotaline-treated rats. *J Mol Cell Cardiol.* **32** (2000); 2315- 2326
56. Shipley RA, Shipley LJ, Wearn JT: The capillary supply in normal and hypertrophied hearts of rabbits. *J Exp Med* **65** (1937); 29-42
57. Smith HJ, Nuttall A: Experimental models of heart failure. *Cardiovasc Res* **19** (1985); 181-186
58. Starksen NF, Simpson PC, Bisphoric N, Coughlin SR, Lee WMF, Escobedo JA, Williams LT: Cardiac myocyte hypertrophy is associated with c-myc proto-oncogen expression. *Proc Natl Acad Sci USA* **83** (1986); 8348-8350

59. Starling EH and Visscher MB.: The regulation of the energy output of the heart. *J Physiol* **62** (1926): 243–261
60. Steinfath M, Chen Y-Y, Lavický J, Magnussen O, Nose M, Rosswag S, Schmitz W, Scholz H: Cardiac α_1 -adrenoceptor densities in different mammalian species. *Br J Pharmacol* **102** (1992a); 185-188
61. Steinfath M, Danielsen W, Leyen H van der, Mende U, Meyer W, Neumann J, Nose J, Reich T, Schmitz W, Scholz H, Starbatty J, Stein B, Döring V, Kalmar P, Haverich A: Reduced α_1 - and β_2 -adrenoceptor-mediated positiv inotropic effects in human end-stage heart failure. *Br J Pharmacol* **105** (1992b); 463-469
62. Sudgen PH, Clerk A: Cellular mechanisms of cardiac hypertrophy. *J Mol Med* **76** (1998); 725-746
63. Sugita T, Hyers TM, Dauber IM, Wagner WW, McMurtry IF, Reeves JT: Lung vessel leak precedes right ventricular hypertrophy in monocrotaline-treated rats. *J Appl Physiol* **54** (1983); 371-374
64. Terzic A, Puceat M, Vassorit G, Vogel SM: Cardiac α_1 -adrenoceptors: an overview. *Pharmacol Rev* **45** (1993); 147-175
65. Vago T, Bevilaqua M, Norbiato G, Baldi G, Chebat E, Bertora P, Baroldi G, Accinni R: Identification of α_1 -adrenergic receptors on sarcolemmal from normal subjects and patients with idiopathic dilated cardiomyopathy: Characteristics and linkage to GTP-binding protein. *Circ Res* **64** (1989); 474-481
66. Vescovo G, Jones SM, Harding SE, Poole-Wilson PA: Isoproterenol sensitivity of isolated cardiac myocytes from rats with monocrotaline-induced right-sided hypertrophy and heart failure. *J Mol Cell Cardiol* **21** (1998); 1047-1061

67. Viko H, Osnes JB, Sjetnan AE, Skomedal T: Improved isolation of cardiomyocytes by trypsination in addition to collagenase treatment. *Pharmacol Toxicol* **76** (1995); 68-71
68. Wagner JG, Petry TW, Roth RA: Characterization of monocrotaline pyrrole-induced DNA cross-link in pulmonary artery endothelium. *Am J Physiol* **264** (1993); L517-L522
69. Weinberg DH, Trivedi P, Tan CP, Mitra S, Perkins-Barrow A, Borkowski D, Strader CD, Bayne M: Cloning, expression and characterization of human α -adrenergic receptors α_{1A} , α_{1B} and α_{1C} . *Biochem Biophys Res Commun* **201** (1994); 1296-1304
70. Wilson DW, Lamé MW, Dunston SK, Segall HJ: DNA damage cell checkpoint activities are altered in monocrotaline pyrrole-induced cell cycle arrest in human pulmonary artery endothelial cells. *Toxicol Appl Pharmacol* **166** (2000); 69-80
71. Wilson DW, Segall HJ: Changes in type II cell populations in monocrotaline pneumotoxicity. *Am J Pathol* **136** (1990); 1293-1299
72. Wilson DW, Segall HJ, Pan LC, Dunston SK: Progressive inflammatory and structural changes in the pulmonary vasculature of monocrotaline-treated rats. *Microvasc Res* **38** (1989); 57-80
73. Wolff DW, Dang HK, Liu MF, Feffries WB, Scofield MA: Distribution of α_1 -adrenergic receptor mRNA species in rat heart. *J Cardiovasc Pharmacol* **32** (1998); 117-122
74. Yang M, Ruan J, Voller M, Schalken J, Michel MC: Differential regulation of human α_1 -adrenoceptors. *Naunyn-Schmiedeberg's Arch Pharmacol* **359** (1999); 439-446

75. Yoshi H, Tobise K, Ondera S: Intraventricular changes in the β -adrenoceptor-adenylate-cyclase system of the rat heart with the progress of monocrotaline-induced right ventricular hypertrophy. *Jpn Circ J* **58** (1994); 855-865

76. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR: Cardiac adrenergic receptor effects of carvedilol. *Eur Heart J* **17 (Suppl B)** (1996); 8-16